

Urinary Angiotensin-2 Levels are Associated with Risk of Adverse Kidney Outcomes in the Intensive Care Unit

Zoie A. Bailey¹, Jordan J. Lo¹, Ayesha Khader², Julia Hallowell¹, Sarah L. Speckmaier¹, Leila R. Zelnick³, Ian B. Stanaway³, W.

Conrad Liles^{2,4}, and Pavan K. Bhatraju^{1,3,4}

¹Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington Medical Center, Seattle, WA

²Department of Medicine, University of Washington, Seattle, WA

³Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington Medical Center, Seattle, WA

⁴Sepsis Center of Research Excellence – University of Washington (SCORE-UW), Seattle, WA



UNIVERSITY of WASHINGTON

Introduction

- Acute kidney injury (AKI) is a heterogeneous syndrome associated with increased mortality, and hospital stay, affecting 30-60% of critically ill patients
- Limitations to serum creatinine (SCr) and urine output as a kidney function indicator
- Treatment is mainly supportive and not targeted to treat AKI
- Angiotensin-2 (Ang-2) promotes endothelial dysfunction by increasing vascular permeability and destabilization
 - Elevated plasma Ang-2 are associated with adverse kidney outcomes
- Here we sought to understand the association between urinary Ang-2 (uAng-2) and kidney outcomes

Methods and Materials

Clinical Cohort

We analyzed 192 COVID-19 ICU participants. AKI was defined as an increase in SCr during hospitalization ≥ 0.3 mg/dl or 50% from the SCr on study enrollment, consistent with KDIGO guidelines.

Immunoassay measurement

Urinary and plasma samples were collected to measure Ang-2 by immunoassay using the MesoScale Discovery platform.

Statistical Analysis

Participants were stratified into tertiles (n=64) based on uAng-2 concentrations normalized to urine creatinine. Participants with uAng-2 concentrations below the lower limit of detection (LLOD) of the assay were imputed using $(0.5) \times \text{LLOD}$. Then a log-linear regression was used to determine the risk of AKI, mortality and renal replacement therapy (RRT).

Table 1: Patient Characteristics	N=64	N=64	N=64
	Tertile 1	Tertile 2	Tertile 3
Age, years, mean (SD)	55±18	56±15	55±15
Sex, male (%)	41 (64)	44 (68)	40 (62)
BMI kg/m ² , mean (SD)	30±8	33±12	30±8
Serum Creatinine (mg/dL)	1.19	1.07	1.87
SOFA Score, mean (SD)	6.7±4.2	6.0±4.3	7.9±5.1
uAng-2 Range (pg/mg)	1 - 16	16 - 123	130 - 189,129
Diabetes mellitus, n (%)	14 (21)	18 (28)	27 (42)
Hypertension, n (%)	34 (53)	37 (57)	31 (48)
Invasive Mechanical Ventilation, n(%)	41 (64)	38 (59)	51 (79)

Table 2: Outcomes	N=64	N=64	N=64
	Tertile 1	Tertile 2	Tertile 3
Hospital Mortality, n (%)	17 (26)	20 (31)	30 (46)
Hospital RRT, n (%)	6 (9)	3 (5)	14 (22)
Acute Kidney Injury, n (%)	22 (34)	21 (32)	42 (65)
Stage 1	10	10	12
Stage 2	2	6	6
Stage 3	10	5	24

Results

Demographics (65% men, 55 years old)

- 44% developed AKI during hospitalization
- 35% in-hospital mortality
- 12% received renal replacement therapy

Tertile 2

- No significant difference from tertile 1 in risk AKI, death or RRT

Tertile 3

- Participants had an increased risk of AKI development or mortality during hospitalization compared to tertile 1
- Higher rate of RRT, although not statistically significant




Figure 1: Risk exposure for hospital AKI and mortality in creatinine-normalized urine Ang-2

Discussion

- Individuals with an increase in Ang-2 exhibit a higher risk of AKI and mortality compared to those with a low Ang-2 concentration.
- Despite the non-significance in RRT, more than half of participants (61%) who underwent RRT had an elevated Ang-2 concentration.
- Interestingly, plasma and urinary Ang-2 were minimally correlated (Pearson's correlation $r=0.28$) suggesting possible local peritubular capillary leak.

Conclusions

Here we examined the association between Ang-2, an endothelial dysfunction biomarker, and kidney outcomes. **Elevated uAng-2 are associated with the development of AKI and mortality in the ICU.** Although the source of Ang-2 in the urine is not well understood, our findings suggest that urinary Ang-2 is a novel biomarker of kidney outcomes and may provide insight of kidney function.

Acknowledgments: This study was funded by NIH grants R01DK124063 and R01DK124063-01S1

Zoie Bailey
zb8@uw.edu



THE 29TH INTERNATIONAL CONFERENCE ON
ADVANCES IN CRITICAL CARE NEPHROLOGY
AKI & CRRT 2024

MARCH 12-15, 2024 SAN DIEGO, CALIFORNIA